Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

The impact and indications for Oncotype DX on adjuvant treatment recommendations when third-party funding is unavailable.

Chin-Lenn L, De Boer RH, Segelov E, Marx GM, Hughes TM, McCarthy NJ, White SC, Foo SS, Rutovitz JJ, Della-Fiorentina S, Jennens R, Antill YC, Tsoi D, Cronk MF, Lombard JM, Kiely BE, Chirgwin JH, Gorelik A, Mann GB.

Asia Pac J Clin Oncol. 2018 Dec;14(6):410-416. doi: 10.1111/ajco.13075. Epub 2018 Sep 30.

PMID:
30270527
2.

Cisplatin-induced syndrome of inappropriate antidiuretic hormone secretion (SIADH) with life-threatening hyponatraemia.

Tan AC, Marx GM.

BMJ Case Rep. 2018 Jan 31;2018. pii: bcr-2017-222948. doi: 10.1136/bcr-2017-222948.

3.

Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer.

Tan AC, Li BT, Nahar K, Danieletto S, Fong ES, Currer T, Parasyn A, Middleton P, Wong H, Smart D, Rutovitz JJ, McCloud P, Hughes TM, Marx GM.

Asia Pac J Clin Oncol. 2018 Apr;14(2):e161-e166. doi: 10.1111/ajco.12779. Epub 2017 Sep 29.

PMID:
28960862
4.

The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.

Li BT, Barnes TA, Chan DL, Naidoo J, Lee A, Khasraw M, Marx GM, Kris MG, Clarke SJ, Drilon A, Rudin CM, Pavlakis N.

Lung Cancer. 2016 Dec;102:21-27. doi: 10.1016/j.lungcan.2016.10.004. Epub 2016 Oct 17.

5.

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer.

Mahon KL, Lin HM, Castillo L, Lee BY, Lee-Ng M, Chatfield MD, Chiam K, Breit SN, Brown DA, Molloy MP, Marx GM, Pavlakis N, Boyer MJ, Stockler MR, Daly RJ, Henshall SM, Horvath LG.

Br J Cancer. 2015 Apr 14;112(8):1340-8. doi: 10.1038/bjc.2015.74. Epub 2015 Mar 31.

6.

Geriatric assessment of older patients with cancer in Australia--a multicentre audit.

Lakhanpal R, Yoong J, Joshi S, Yip D, Mileshkin L, Marx GM, Dunlop T, Hovey EJ, Della Fiorentina SA, Venkateswaran L, Tattersall MH, Liew S, Field K, Singhal N, Steer CB.

J Geriatr Oncol. 2015 May;6(3):185-93. doi: 10.1016/j.jgo.2015.03.001. Epub 2015 Mar 23.

PMID:
25813881
7.

Severe symptomatic hypocalcaemia following a single dose of denosumab.

McLachlan JM, Marx GM, Bridgman M.

Med J Aust. 2013 Aug 19;199(4):242-3. No abstract available.

PMID:
23984777
8.

Cancer in older people: a tale of two disciplines.

Steer CB, Marx GM, Singhal N, McJannett M, Goldstein D, Prowse R.

Intern Med J. 2009 Nov;39(11):771-5. doi: 10.1111/j.1445-5994.2009.02056.x. Review.

PMID:
19912404
9.

Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling.

Zhao L, Lee BY, Brown DA, Molloy MP, Marx GM, Pavlakis N, Boyer MJ, Stockler MR, Kaplan W, Breit SN, Sutherland RL, Henshall SM, Horvath LG.

Cancer Res. 2009 Oct 1;69(19):7696-703. doi: 10.1158/0008-5472.CAN-08-4901. Epub 2009 Sep 22.

10.

Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study.

Steer CB, Chrystal K, Cheong KA, Galani E, Marx GM, Strickland AH, Yip D, Lofts F, Gallagher C, Thomas H, Harper PG.

Gynecol Oncol. 2006 Nov;103(2):439-45. Epub 2006 Apr 27.

PMID:
16643993
11.

Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients.

Marx GM, Blake GM, Galani E, Steer CB, Harper SE, Adamson KL, Bailey DL, Harper PG.

Ann Oncol. 2004 Feb;15(2):291-5.

12.

Pseudomyxoma peritonei: the 'controversial' disease.

Galani E, Marx GM, Steer CB, Culora G, Harper PG.

Int J Gynecol Cancer. 2003 Jul-Aug;13(4):413-8. Review.

PMID:
12911716
13.

Combined modality treatments in early non-small cell lung cancer.

Harper P, Marx GM.

Lung Cancer. 2002 Oct;38(1):S23-5. Review. No abstract available.

PMID:
12367810
14.

Quality of life: it's never too late.

Steer CB, Marx GM, Galani E, Harper PG, Khayat D.

J Clin Oncol. 2002 Jul 1;20(13):2915-7. No abstract available.

PMID:
12089218
15.

Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock!

Marx GM, Steer CB, Harper P, Pavlakis N, Rixe O, Khayat D.

J Clin Oncol. 2002 Mar 15;20(6):1446-8. No abstract available.

PMID:
11896090
16.

Elevated alpha-foetoprotein and hepatic metastases--it's not always what it seems!

Marx GM, Boyce A, Goldstein D.

Ann Oncol. 2002 Jan;13(1):167-9.

17.

Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme.

Marx GM, Pavlakis N, McCowatt S, Boyle FM, Levi JA, Bell DR, Cook R, Biggs M, Little N, Wheeler HR.

J Neurooncol. 2001 Aug;54(1):31-8.

PMID:
11763420
18.

Is there quality in clinical benefit?

Steer CB, Marx GM, Harper PG.

Ann Oncol. 2001 Sep;12(9):1191-3. No abstract available.

Supplemental Content

Support Center